This activity will provide an overview of the current state of management of upper GI cancers. Specifically it will focus on esophageal, gastric, and pancreatic tumors. Recently published clinical trials and ongoing trials will be reviewed in detail.
This lecture will cover contemporary management of rectal and anal cancer. For rectal cancer, contemporary trials using total neoadjuvant therapy and non-operative management will be reviewed with specific emphasis on various approaches, merits of different sequencing options, and future trials. Management of anal cancer will focus on modern radiotherapy techniques as well as current efforts aimed at toxicity mitigation or treatment de-intensification/intensification for favorable/unfavorable risk patients respectively.
The activity is designed to meet the interests of radiation oncologists, radiation oncology residents, medical and clinical physicists, radiation therapists, radiation dosimetrists, nurses and all other health professionals involved in the field of radiation oncology.
Upon completion of this activity, participants should be able to do the following:
- Provide a summary of recent important published trials in pancreatic cancer, gastric cancer, and esophageal cancer.
- Discuss the ongoing trials in the space of upper GI cancers along with unanswered questions.
- Review current new technologies (CT and MR based adaptive therapy) and how these may help patients.
- Understand various sequencing strategies for radiation as part of total neoadjuvant therapy in rectal cancer and pros/cons of various approaches.
- Implement modern radiotherapy techniques for management of anal cancer.
William A. Hall, MD is employed by the Medical College of Wisconsin and has received compensation from Aktis Oncology and grant/research funding from Elekta AB.
Jordan R. Kharofa, MD is employed by the University of Cincinnati and has no financial relationships with a commercial interest.
All relevant financial relationships have been mitigated.
The person(s) above served as the developer(s) of this activity. Additionally, the Annual Refresher Course Planning Committee had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.75 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.75 Certificate of AttendanceThis activity was designated for 1.75 AMA PRA Category 1 Credit™.